Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

LEVOFLOXACIN

All products: general benefit

Other products in the same Health Canada class (J01MA) — coverage varies; not interchangeable

  • Ciprofloxacin (Cipro): general benefit, Limited Use 533, Not a benefit
  • Moxifloxacin (Avelox): general benefit, Not a benefit
  • Norfloxacin (Noroxin): general benefit, Not a benefit
  • Ciprofloxacin + ciprofloxacin base (Cipro XL): limited Use 394, Not a benefit

Mint-Levofloxacin · DIN 02505797 · 250mg · tablet

General benefit; Health Canada lists this DIN as Cancelled post market since 2026-04-02 — choose a marketed DIN from the same-category list.Discontinued 2026-04-02 · checked 2026-09-19
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2026-04-02 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2026-04-02 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Mint-Levofloxacin · DIN 02505797 Manufacturer: Mint Pharmaceuticals Inc.; listing date 2021-10-29 Health Canada: Cancelled post market since 2026-04-02 · brand MINT-LEVOFLOXACIN · ATC J01MA12 LEVOFLOXACIN · form Tablet · route Oral · ingredients LEVOFLOXACIN (LEVOFLOXACIN HEMIHYDRATE) 250 MG · company Mint pharmaceuticals inc · schedule Prescription
Check this DIN again · Health Canada product record

Mint-Levofloxacin: Formulary list price $1.2038/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1.2038 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99517 · Verify on the e-Formulary ↗ (DIN 02505797)

Source record
DIN 02505797: Mint-Levofloxacin Raw flags: sec3=Y Item: 084000051; group id 134; item number 0225; lccId None; manufacturer id MIN Source form: Tab; strength: 250mg Recorded listing: General benefit Source prices (unrounded): $1.2038; ministry $1.2038 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02505797 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99517
Interchangeable products
Act Levofloxacin · DIN 02315424 · $1.2038 Apo-Levofloxacin · DIN 02284707 · $1.2038 Jamp Levofloxacin · DIN 02508443 · $1.2038 Levaquin · DIN 02236841 · not recorded Novo-Levofloxacin · DIN 02248262 · $1.2038 Riva-Levofloxacin · DIN 02492725 · $1.2038 Sandoz Levofloxacin · DIN 02298635 · $1.2038
Shortage status: not checked (no credentials)
Health Canada lists this DIN as Cancelled post market since 2026-04-02 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (08:40 Miscellaneous Anti-Infectives) and how they are covered

Matched class: 08:40 Miscellaneous Anti-Infectives

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Some products covered without a code (check the product listing): CIPROFLOXACIN, MOXIFLOXACIN HYDROCHLORIDE, NORFLOXACIN, SULFAMETHOXAZOLE & TRIMETHOPRIM, TRIMETHOPRIM 08:40 Miscellaneous Anti-Infectives

CIPROFLOXACIN

· 44 products · Limited Use, codes 533 (1), Listed, not a benefit (3), General benefit (40) · strengths: 10g/100mL, 250mg, 500mg, 750mg · Oral Susp, Tab

MOXIFLOXACIN HYDROCHLORIDE

· 12 products · Listed, not a benefit (1), General benefit (11) · strengths: 400mg · Tab

NORFLOXACIN

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 400mg · Tab

CIPROFLOXACIN HCL & CIPROFLOXACIN BASE

· 2 products · Listed, not a benefit (1), Limited Use, codes 394 (1) · strengths: 500mg · ER Tab

SULFAMETHOXAZOLE & TRIMETHOPRIM

· 9 products · Listed, not a benefit (6), General benefit (3) · strengths: 40mg & 8mg/mL, 400mg & 80mg, 800mg & 160mg · O/L, Tab

TRIMETHOPRIM

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 100mg, 200mg · Tab

LINEZOLID

· 6 products · Off-Formulary Interchangeable, not an ODB benefit (2), Listed, not a benefit (1), Limited Use, codes 362, 363, 364 (3) · strengths: 2mg/mL, 600mg · Inj-300mL Pk, Tab

CEFEPIME

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 1g, 2g · Inj Pd-Vial Pk

ERTAPENEM

· 5 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 1g/Vial · Inj Pd-Vial Pk Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 08:40
Full class listing Related classes: 08:08 Anthelmintics, 08:12 Antibiotics, 08:14 Antifungals, 08:16 Antitubercular Agents, 08:18 Antivirals, 08:20 Plasmodicides (Antimalarials), 08:24 Sulfonamides, 08:30 Antiprotozoals, 08:32 Trichomonacides, 08:36 Urinary Anti-Infectives Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS APO-LEVOFLOXACIN (levofloxacin tablets) are indicated for the treatment of adults with bacterial infections caused by susceptible strains of the designated microorganisms in the infections listed below. • To reduce the development of drug-resistant bacteria and maintain the effectiveness of APO- LEVOFLOXACIN and other antibacterial drugs, APO-LEVOFLOXACIN should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. • Upper Respiratory Tract Acute bacterial sinusitis (mild to moderate) due to Streptococcus pneumoniae, Haemophilus influenzae, or Moraxella (Branhamella) catarrhalis. Restrict the use of APO-LEVOFLOXACIN to settings where no other treatment options exist, and the clinical presentation meets the diagnostic criteria for acute bacterial sinusitis.1 • Lower Respiratory Tract Acute bacterial exacerbations of chronic bron… https://pdf.hres.ca/dpd_pm/00078730.PDF PM date: JUN 24, 2009 Source product: APO-LEVOFLOXACIN; DIN 02284707; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.